Read Award-Winning editorial content & comparison charts as a cardiology research tool for specifying, recommending and approving technology/device purchases.
Dapagliflozin Did Not Significantly Reduce Organ Failure or Death in High-Risk Hospitalized COVID-19 Patients
Phase III DARE-19 trial shows SGLT2 inhibitor is well-tolerated in acutely ill patients
Dapagliflozin did not significantly reduce organ failure or death in high-risk hospitalized COVID-19 patients in the DARE-19 trial results, presented at ACC.21.
May 18, 2021 Dapagliflozin (Farxiga), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, did not significantly reduce the risk of organ failure or death or improve recovery in patients hospitalized with COVID-19 (SARS-CoV-2) who are at high risk of developing serious complications compared to placebo, according to data presented at the American College of Cardiology (ACC) 2021 Scientific Session.
email article
One thing an SGLT2 won t do? Dapagliflozin (Farxiga) flopped for hospitalized COVID-19 patients in the phase III DARE-19 trial. Full results are coming at the American College of Cardiology meeting. (
Pharmaphorum)
Johnson & Johnson s COVID vaccine is now the center of attention for rare thrombotic events. (FDA)
Post-discharge anticoagulation for COVID-19 patients was associated with 46% lower risk of major thromboembolism or death in one hospital system s registry data. (
Blood)
Kaiser Health News.
Journal of the American College of Cardiology)
Medtronic has a class I recall out on Evera, Viva, Brava, Claria, Amplia, Compia, and Visia ICDs and CRT-Ds due to short circuiting that depletes the battery, sometimes in just 1 day, the FDA cautioned.
Praluent OK'd for HoFH; Contraception in Cardiology; Cutting Amputations medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.